Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration

Buse, John B.; Han, Jenny; Miller, Stephan; MacConell, Leigh; Pencek, Richard; Wintle, Matthew

doi:10.1185/03007995.2014.896329

Cited by 7 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30][31][32][33] When added to insulin, adjunctive exenatide BID was associated with statistically significant greater weight loss or mitigation of weight gain compared with placebo. 34 When added to metformin and sulphonylurea, liraglutide resulted in greater weight loss compared to glargine over 26 weeks (LEAD-5); (treatment difference: -3.43kg; 95% CI 4.00, 2.86; p<0.0001). 35 The addition of insulin detemir to liraglutide 1.8mg + metformin treatment did not result in weight gain over 52 weeks in patients who already lost 3.5kg on liraglutide 1.8mg + metformin prior to receiving detemir.…”

Section: Impact Of Glp-1 Ras On Weight Loss In Patients With T2dmmentioning

confidence: 99%

The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

2015

View full text Add to dashboard Cite

Obesity contributes to the pathogenesis of type 2 diabetes (T2DM) and cardiovascular disease. A modest weight loss of 5-10% can have significant impact on glucose control, medications use and patients' functionality and quality of life. Until recently, only orlistat was approved in Europe for weight loss. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve glycaemia in patients with T2DM with an added benefit of weight reduction. However, the weight loss varies considerably within class and between individuals with up to 30% of patients not losing weight with GLP-1 RA treatment.GLP-1 RAs were placed as a possible second-line treatment as an add on to metformin by the latest ADA/EASD joint guidelines while NICE placed them as third-line agents for patients with T2DM and a body mass index (BMI) ≥35kg/m 2 and inadequate glycaemic control. NICE recommended that GLP-1 RAs can be used in patients with BMI <35kg/m 2 in ethnic groups, when used as an alternative to insulin where insulin treatment has vocational implications, or if weight loss would be beneficial for other medical reasons. A GLP-1 RA (Saxenda) has recently been approved by the FDA and EMA as a weight loss treatment in patients without T2DM.This paper aims to review the impact of GLP-1 RA treatment on weight loss in patients with and without diabetes, from clinical trials as well as real-life UK data from the ABCD nationwide audits, and also discuss the future role of GLP-1 RAs.

show abstract

Section: Impact Of Glp-1 Ras On Weight Loss In Patients With T2dmmentioning

confidence: 99%

The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

2015

View full text Add to dashboard Cite

show abstract

Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)

Brunt

Miličević³

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options

Raccah

2017

Diabetes & Metabolism

View full text Add to dashboard Cite

Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration

Abstract: Addition of fixed-dose exenatide BID to optimized insulin glargine, regardless of the extent of insulin titration, significantly improved glycemia without increasing hypoglycemia risk, while mitigating insulin-induced weight gain in this post-hoc analysis.

Cited by 7 publications

References 39 publications

The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

The role of GLP‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes

Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)

Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options

Contact Info

Product

Resources

About